Search | IOVS | ARVO Journals

Showing 1 – 20 of 26

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2015

Proteomic Mass Spectroscopy Profiling of Proteins Secreted from an Encapsulated Cell Technology (ECT) Implant Device

Lisa D. Orecchio; Michael Rivera; Edward Brissette; Cahil McGovern; Arne Nystuen; Rhett Schiffman; Konrad Kauper

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):229.

ARVO Annual Meeting Abstract June 2015

Evaluation of Retinal Structure and Function of Rabbits Following Continuous VEGF Inhibition by Encapsulated Cell Therapy (ECT)

Alline M. A. Lelis; Michael Rivera; Lisa D. Orecchio; Pam Heatherton; Edward Brissette; Alice Lee; Cahil McGovern; Arne Nystuen; Rhett M Schiffman; Konrad Kauper

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):232.

ARVO Annual Meeting Abstract April 2014

Design Considerations and Performance of a Next-Generation Encapsulated Cell Technology Intraocular Implant Delivering VEGF-Antagonist

Konrad Kauper; Michael Rivera; John Mills; Alline Lelis; Megan Billings; Cahil McGovern; Arne Nystuen; Sandy Sherman; Pam Heatherton; Rhett Schiffman

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):441.

ARVO Annual Meeting Abstract June 2013

Feasibility of Cryopreservation of the Encapsulated Cell Technology Devices

Cahil McGovern; John Duggan; Crystal Cortellessa; Sandy Sherman; Melissa Stiles; Konrad Kauper; Allyse Mazzarelli; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3294.

ARVO Annual Meeting Abstract June 2013

Continuous Intraocular Drug Delivery over 5 ½ Years: Ciliary Neurotrophic Factor (CNTF)Production by Encapsulated Cell Technology Implants Treating Patients with Retinitis Pigmentosa and Geographic Atrophy

Konrad Kauper; Cahil McGovern; Paul Stabila; Sandy Sherman; Pam Heatherton; Brenda Dean; Crystal Cortellessa; Alice Lee; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3295.

Clinical and Epidemiologic Research November 2012

Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases

PDF

Konrad Kauper; Cahil McGovern; Sandy Sherman; Pam Heatherton; Rob Rapoza; Paul Stabila; Brenda Dean; Alice Lee; Suzanna Borges; Bruce Bouchard; Weng Tao
TAGS: ciliary neurotrophic factor, implants, degenerative disorders
Invest. Ophthalmol. Vis. Sci.. 2012; 53(12):7484-7491. https://doi.org/10.1167/iovs.12-9970

ARVO Annual Meeting Abstract March 2012

Long-Term, Sustained Intraocular Delivery of a VEGF Antagonist Using Encapsulated Cell Technology Implant for the Treatment of Choroidal Neovascular Diseases

Konrad Kauper; Vincent Ling; Sue Elliot; Cahil McGovern; Sandy Sherman; Brenda Dean; Lisa Orecchio; Mike Rivera; Pam Heatherton; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):455.

ARVO Annual Meeting Abstract March 2012

Evaluation of a Candidate Cell Line Employed to Deliver an Antiangiogenic Factor Using Encapsulated Cell Technology

Cahil McGovern; Sandy Sherman; Crystal Cortellessa; Suzanna Borges; Melissa Stiles; Karen Ahola; Alice Lee; Konrad Kauper; Bruce Bouchard; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):465.

ARVO Annual Meeting Abstract April 2011

Antibody Scaffold-based Biotherapeutics Are Secreted From Ophthalmic Ect Devices

Vincent Ling; Susan Elliott; Paul Stabila; Brenda Dean; Lisa D. Orecchio; Konrad Kauper; Cahil McGovern; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):474.

ARVO Annual Meeting Abstract April 2011

Pharmacokinetics and Bioactivity of a Potent VEGF Inhibitor Following Sustained Intraocular Delivery to the Rabbit Eye Using Neurotech’s Encapsulated Cell Technology

Konrad Kauper; Paul Stabila; Vincent Ling; Sue Elliot; Cahil McGovern; Sandy Sherman; Mike Rivera; Alline Lelis; Pam Heatherton; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3223.

ARVO Annual Meeting Abstract April 2011

Evaluation of Candidate Cell Lines Employed to Deliver Different Antiangiogenic Factors Intraocularly Using Encapsulated Cell Technology

Cahil McGovern; Sandy Sherman; Crystal Cortellessa; Konrad Kauper; Michael Rivera; Melissa Stiles; Suzanna Borges; Vincent Ling; Bruce Bouchard; Weng Tao

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3230.

ARVO Annual Meeting Abstract April 2010

Intraocular Delivery of CNTF Using Modified NT-501 Devices Manufactured With Different Medias and Membranes of Different Porosities

C. McGovern; S. Sherman; K. Kauper; M. R. Rivera; B. Bouchard; A. Lee; S. Mateus; P. Stabila; W. Tao

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):5305.

ARVO Annual Meeting Abstract April 2010

Sustained Intraocular Delivery of a Receptor Antibody Using an Encapsulated Cell Technology Implant

K. Kauper; P. Stabila; S. Elliot; M. Rivera; P. Heatherton; S. Sherman; C. McGovern; M. Stiles; B. Dean; W. Tao

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):5317.

ARVO Annual Meeting Abstract April 2010

Investigation of a High Permselectivity Membrane and Its Effect on Encapsulated Cell Viability and Therapeutic Protein Release Over a 1-Year Implantation Period in Rabbits

M. R. Rivera; K. Kauper; S. Sherman; C. McGovern; P. Heatherton; B. Bouchard; M. Stiles; K. Abrams; W. Tao

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):5320.

ARVO Annual Meeting Abstract April 2009

Optimized Process and Analytical Controls Ensure the Successful Technical Transfer of Encapsulated Cell Technology (ECT) Capsule Manufacturing to a Contract Medical Device Manufacturer

K. Kauper; S. Sherman; J. Mills; M. Rivera; C. Bray; C. McGovern; B. Bouchard; P. St. Germain; W. Tao

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):5983.

ARVO Annual Meeting Abstract April 2009

Long-term Sustained Intraocular Delivery of CNTF by Encapsulated Cell Technology Implants in Patients with Retinitis Pigmentosa

C. McGovern; K. Kauper; S. Sherman; S. Mateus; P. Stabila; A. Lee; B. Bouchard; W. Tao

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):5991.

ARVO Annual Meeting Abstract May 2008

Long Term in vitro Stability of CNTF Secreting NT-501 Implants

C. McGovern; K. Kauper; S. Sherman; S. Mateus; P. Stabila; A. Lee; B. Bouchard; W. Tao

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):1828.

ARVO Annual Meeting Abstract May 2008

18-Month Intraocular Viability and Drug Delivery Kinetics of Polymer Encapsulated Cells Used in the Treatment of Retinal Disorders

K. Kauper; P. Heatherton; C. McGovern; S. Sherman; A. Lee; B. Bouchard; P. Stabila; W. Tao

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):3181.

ARVO Annual Meeting Abstract May 2007

Safety and Pharmacokinetics of an Injectable Encapsulated Cell Technology Implant

K. A. Kauper; P. Heatherton; J. Lydon; J. Mills; A. Lee; C. McGovern; M. Bock; W. Tao

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):627.

ARVO Annual Meeting Abstract May 2007

Effect of Membrane Porosity on CNTF Delivery Using the NT-501 Micronized Device

C. McGovern; K. Kauper; S. Sherman; S. Mateus; P. Stabila; J. Lydon; A. Lee; B. Dean; W. Tente; W. Tao

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):628.

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Proteomic Mass Spectroscopy Profiling of Proteins Secreted from an Encapsulated Cell Technology (ECT) Implant Device

Evaluation of Retinal Structure and Function of Rabbits Following Continuous VEGF Inhibition by Encapsulated Cell Therapy (ECT)

Design Considerations and Performance of a Next-Generation Encapsulated Cell Technology Intraocular Implant Delivering VEGF-Antagonist

Feasibility of Cryopreservation of the Encapsulated Cell Technology Devices

Continuous Intraocular Drug Delivery over 5 ½ Years: Ciliary Neurotrophic Factor (CNTF)Production by Encapsulated Cell Technology Implants Treating Patients with Retinitis Pigmentosa and Geographic Atrophy

Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases

Long-Term, Sustained Intraocular Delivery of a VEGF Antagonist Using Encapsulated Cell Technology Implant for the Treatment of Choroidal Neovascular Diseases

Evaluation of a Candidate Cell Line Employed to Deliver an Antiangiogenic Factor Using Encapsulated Cell Technology

Antibody Scaffold-based Biotherapeutics Are Secreted From Ophthalmic Ect Devices

Pharmacokinetics and Bioactivity of a Potent VEGF Inhibitor Following Sustained Intraocular Delivery to the Rabbit Eye Using Neurotech’s Encapsulated Cell Technology

Evaluation of Candidate Cell Lines Employed to Deliver Different Antiangiogenic Factors Intraocularly Using Encapsulated Cell Technology

Intraocular Delivery of CNTF Using Modified NT-501 Devices Manufactured With Different Medias and Membranes of Different Porosities

Sustained Intraocular Delivery of a Receptor Antibody Using an Encapsulated Cell Technology Implant

Investigation of a High Permselectivity Membrane and Its Effect on Encapsulated Cell Viability and Therapeutic Protein Release Over a 1-Year Implantation Period in Rabbits

Optimized Process and Analytical Controls Ensure the Successful Technical Transfer of Encapsulated Cell Technology (ECT) Capsule Manufacturing to a Contract Medical Device Manufacturer

Long-term Sustained Intraocular Delivery of CNTF by Encapsulated Cell Technology Implants in Patients with Retinitis Pigmentosa

Long Term in vitro Stability of CNTF Secreting NT-501 Implants

18-Month Intraocular Viability and Drug Delivery Kinetics of Polymer Encapsulated Cells Used in the Treatment of Retinal Disorders

Safety and Pharmacokinetics of an Injectable Encapsulated Cell Technology Implant

Effect of Membrane Porosity on CNTF Delivery Using the NT-501 Micronized Device

To View More...

You must be signed into an individual account to use this feature.